Previous 10 | Next 10 |
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing i...
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibit...
Truist has downgraded Assembly Biosciences ( NASDAQ: ASMB ) to hold from buy due to a recent clinical trials failure and a lack of near-term catalysts. The firm also cut its price target to $2 from $11 (~30% upside based on Friday's close). Analyst Nicole Germino cited...
Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement into clinical studies before year...
Assembly Biosciences ( NASDAQ: ASMB ) on Wednesday said its current CEO John McHutchison would step down at the end of the year. The company's board selected current president and COO Jason Okazaki to succeed McHutchison as top boss, ASMB said in a statement . McHu...
Summary Today, we revisit Arbutus Biopharma Corporation for the first time in almost a year. An interesting 'sum of the parts' story seems to be emerging around the company and the stock. An investment analysis follows in the paragraphs below. "I could easily for...
- Renowned virologist, Nobel laureate and Assembly Bio board member, Sir Michael Houghton, PhD, will join company leadership for the discussion - SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnolog...
Assembly Biosciences press release ( NASDAQ: ASMB ): Q2 GAAP EPS of -$0.51. Cash, cash equivalents and marketable securities were $128.6 million as of June 30, 2022, compared to $146.5 million as of March 31, 2022. The company’s cash position is projected to fu...
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results ...
Arbutus Biopharma ( NASDAQ: ABUS ) on Wednesday said its phase 2a hepatitis B virus infection trial with partner Assembly Biosciences ( ASMB ) evaluating a combination involving drug candidates by both companies would continue, despite ASMB's decision to stop deve...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...